Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats

Publication date: Available online 28 April 2017
Source:Clinical Immunology
Author(s): Smadar Gertel, Hussein Mahagna, Gidi Karmon, Abdulla Watad, Howard Amital
Rheumatoid arthritis (RA) is an autoimmune disease characterized by pronounced inflammation and leukocyte infiltration in affected joints.Tofacitinib is new agent, a selective inhibitor of Janus kinase (JAK) signaling pathways mediated by JAK1 and JAK3 and inhibits the key transcription factors STAT1 and STAT3.We investigated the action mechanisms of tofacitinib in rats with adjuvant-induced-arthritis (AIA). AIA-rats were treated orally with tofacitinib or with methotrexate. Arthritis severity and serum C-reactive protein (CRP) levels were evaluated, splenic cells were examined by flow cytometry and cytokines were analyzed by real-time PCR.Tofacitinib markedly reduced the clinical status of treated rats in comparison to control group. Reduced joints inflammation and down-regulated serum CRP levels reflected the clinical manifestations of the treated rats. Tofacitinib down-regulated significantly the frequency of CD4⁺IFN-γ⁺ T cells and reduced IL-1β mRNA expression levels in the spleen of the treated rats.These results show that tofacitinib attenuated arthritis severity, modified splenic populations and cytokine imbalance.



http://ift.tt/2pIaqd5